“Never say “this is the end”: how the eternal outsider Novavax created a competitive vaccine against COVID-19
For decades, the small biotech company Novavax has been trying to develop any approved vaccine, but without success. By January 2020, she had six months of working capital left, and the shares were trading at $4 apiece. Today, Novavax is close to registering its COVID-19 vaccine, which could become one of the most effective, writes The Wall Street Journal.